Cantor Fitzgerald reiterates Overweight on PTC Therapeutics, $137 target
Cantor Fitzgerald maintained an Overweight rating on PTC Therapeutics and kept a $137.00 price target, implying 109.9% upside from the Sep 21 close of $65.26.
Story updates
10:21:06 AM UTC
SquawkNews
Ratings actions GMT) PTC Therapeutics Price Target Raised to $137.00/Share From $130.00 by Cantor FitzgeraldRatings actions